ReviewInflammopharmacology2025
The potential role of carvedilol in COVID-19 management: perspective and take-away.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carvedilol (CVL) is a lipophilic third generation non-selective beta and alpha-1 adrenoceptor blocker. CVL has pleiotropic antioxidant and anti-inflammatory effects by reducing the production of reactive oxygen species (ROS) and inhibiting of inflammatory signaling pathways. In virtue of its antioxidant and anti-inflammatory effects, CVL can ameliorate COVID-19 and related complications. Therefore, the aim of the present review was to illustrate the potential role of CVL in the management of COVID-19. CVL has anti-SARS-CoV-2 activity by inhibiting 3-CLpro, which is involved in the replication of this virus. CVL inhibits the release of pro-inflammatory cytokines, improves anti-inflammatory cytokines, inhibit β/αadrenoceptors-mediated immune activation, and suppression of sympathetic over-activity. Thus, CVL may prevent the association between sympathetic and cytokine storms in COVID-19. These verdicts suggest that CVL through its antioxidant, anti-inflammatory, and blocking of β/αadrenoceptors, might be a possible candidate against COVID-19-induced inflammatory changes, oxidative stress, and the development of dysautonomia. In conclusion, CVL could be a possible drug in the management of COVID-19 by attenuating the development of cytokine and sympathetic storms.
Indexed as
Identifiers
40864414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.